tbuckley/cabot-search huggingface dataset:
The E1841K Mutation in MYH-9 of a Patient with May-Hegglin Anomaly Inhibits the Disassembly of Non-Muscle Myosin IIA (MYH-9) Responsible for the Phenotype of the Disease.
Authors: Koji Miyazaki, Satoshi Komatsu, Mariko Watanabe, Naoya Nakadate, Mitsuo Ikebe, Masaaki Higashihara
Journal: Blood (2004)
Correcting for cell-type effects in DNA methylation studies: reference-based method outperforms latent variable approaches in empirical studies
Authors: Mohammad W. Hattab, Andrey A. Shabalin, Shaunna L. Clark, Min Zhao, Gaurav Kumar, Robin F. Chan, Lin Ying Xie, Rick Jansen, Laura K. M. Han, Patrik K. E. Magnusson, Gerard van Grootheest, Christina M. Hultman, Brenda W. J. H. Penninx, Karolina A. Aberg, Edwin J. C. G. van den Oord
Journal: Genome biology (2017)

Based on an extensive simulation study, McGregor and colleagues recently recommended the use of surrogate variable analysis (SVA) to control for the confounding effects of cell-type heterogeneity in DNA methylation association studies in scenarios where no cell-type proportions are available. As their recommendation was mainly based on simulated data, we sought to replicate findings in two large-scale empirical studies. In our empirical data, SVA did not fully correct for cell-type effects, its performance was somewhat unstable, and it carried a risk of missing true signals caused by removing variation that might be linked to actual disease processes. By contrast, a reference-based correction method performed well and did not show these limitations. A disadvantage of this approach is that if reference methylomes are not (publicly) available, they will need to be generated once for a small set of samples. However, given the notable risk we observed for cell-type confounding, we argue that, to avoid introducing false-positive findings into the literature, it could be well worth making this investment. Please see related Correspondence article: https://genomebiology.biomedcentral.com/articles/10/1186/s13059-017-1149-7 and related Research article: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-0935-y
Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice
Authors: Angela G. Fleischman, Takaomi Sanda, Alejandro Gutierrez, Samuel B Luty, Stephanie G Willis, A. Thomas Look, Brian J. Druker, Jeffrey W Tyner
Journal: Blood (2011)
Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution.
Authors: Bertrand Joly, Valerie Frenkel, Philippe Gaulard, Karim Belhadj, Taoufik El Gnaoui, Jehan Dupuis, Marine Divine, Alain Rahmouni, Christiane Copie Bergman, Marie Helene Delfau-Larue, Felix Reyes, Corinne Haioun
Journal: Blood (2005)
Socioeconomic deprivation and the outcome of pulmonary rehabilitation in England and Wales
Authors: Michael C Steiner, Derek Lowe, Katy Beckford, John Blakey, Charlotte E Bolton, Sarah Elkin, William D -C Man, C Michael Roberts, Louise Sewell, Paul Walker, Sally J Singh
Journal: Thorax (2017)

<h3>Background</h3> Pulmonary rehabilitation (PR) improves exercise capacity and health status in patients with COPD, but many patients assessed for PR do not complete therapy. It is unknown whether socioeconomic deprivation associates with rates of completion of PR or the magnitude of clinical benefits bequeathed by PR. <h3>Methods</h3> PR services across England and Wales enrolled patients to the National PR audit in 2015. Deprivation was assessed using Index of Multiple Deprivation (IMD) derived from postcodes. Study outcomes were completion of therapy and change in measures of exercise performance and health status. Univariate and multivariate analyses investigated associations between IMD and these outcomes. <h3>Results</h3> 210 PR programmes enrolled 7413 patients. Compared with the general population, the PR sample lived in relatively deprived neighbourhoods. There was a statistically significant association between rates of completion of PR and quintile of deprivation (70% in the least and 50% in the most deprived quintiles). After baseline adjustments, the risk ratio (95% CI) for patients in the most deprived relative to the least deprived quintile was 0.79 (0.73 to 0.85), p&lt;0.001. After baseline adjustments, IMD was not significantly associated with improvements in exercise performance and health status. <h3>Conclusions</h3> In a large national dataset, we have shown that patients living in more deprived areas are less likely to complete PR. However, deprivation was not associated with clinical outcomes in patients who complete therapy. Interventions targeted at enhancing referral, uptake and completion of PR among patients living in deprived areas could reduce morbidity and healthcare costs in such hard-to-reach populations.
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Authors: K H Chen, M Wada, K G Pinz, H Liu, K-W Lin, A Jares, A E Firor, X Shuai, H Salman, M Golightly, F Lan, L Senzel, E L Leung, X Jiang, Y Ma
Journal: Leukemia (2017)

The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared surface antigen pool between normal and malignant T-cells. Normal T-cells express CD5 but NK (natural killer) cells do not, positioning NK cells as attractive cytotoxicity cells for CD5CAR design. Additionally, CD5 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas (PTCLs). Here, we report a robust anti-CD5 CAR (CD5CAR) transduced into a human NK cell line NK-92 that can undergo stable expansion ex vivo. We found that CD5CAR NK-92 cells possessed consistent, specific, and potent anti-tumor activity against a variety of T-cell leukemia and lymphoma cell lines as well as primary tumor cells. Furthermore, we were able to demonstrate significant inhibition and control of disease progression in xenograft mouse models of T-ALL. The data suggest that CAR redirected targeting for T-cell malignancies using NK cells may be a viable method for new and complementary therapeutic approaches that could improve the current outcome for patients.
Chronic Administration of Hydroxyurea (HU) and Outcomes in Patients with Sickle Cell Disease (SCD) at a Single Referral Institution
Authors: Rosario Di Maggio, Matthew Hsieh, Courtney Fitzhugh, Xiongce Zhao, Giusi Calvaruso, Paolo Rigano, Disma Renda, Sergio Siragusa, John F. Tisdale, Aurelio Maggio
Journal: Blood (2014)
The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension
Authors: Nicoleta Bertici, Luciana Dehelean, Iosif Marincu, Voicu Tudorache
Journal: European Respiratory Journal (2014)

Background  : The monitoring of evolution in patients with Idiopathic Pulmonary Arterial Hypertension (IPAH) in the context of therapeutic arsenal development more widely and promising is very important, alongside the identification of new prognosis indicators.   Objective : Evaluation the effort tolerance and body composition in IPAH patients and corelation with other prognosis factors.   Methods : The adult IPAH patients9 evolution included in the local registry was monitored for 1 year of specific vasodilator therapy (Bosentan/Ambrisentan/Sildenafil). We evaluated the effort tolerance (through 6 minutes walking test - 6MWT, dyspnea scale Borg, functional class) and body composition (evaluated through impedantometry).   Results : 7 adult patients with IPAH (5 female, 71.42%), average age 41.14 ± 7.7 years were monitorized, majority with severe forms (71.42%), Nyha Class III (57,14%).The 6MWT was slightlylower initially(452.2 m, 76.6% of normal value) and remained almost unchanged (447.8m, 75.4% of normal value). The BMI was normal on 4 patients, 2 patients were with cachexia and one patient was with obesity ( the average BMI/group was 23.10 and remained almost unchanged, 23.24). Body composition was altered in all patients. The proteins were reduced in 5 patients (8.5 kg average / group and after one year fell to 8.1kg). The percent of body fat was high on 4 patients (27.08% average/group and rose to 28.64%), total body water was high on 2 patients (30.74l average/group and rose to 31.72l). Abdominal circumference increased in 4 patients.   Conclusions : Body composition is early altered in IPAH patients and may be a prognosis indicator.
Role of Mitochondrial Metabolism in the Control of Early Lineage Progression and Aging Phenotypes in Adult Hippocampal Neurogenesis
Authors: Ruth Beckervordersandforth, Birgit Ebert, Iris Schäffner, Jonathan Moss, Christian Fiebig, Jaehoon Shin, Darcie L. Moore, Laboni Ghosh, Mariela F. Trinchero, Carola Stockburger, Kristina Friedland, Kathrin Steib, Julia von Wittgenstein, Silke Keiner, Christoph Redecker, Sabine M. Hölter, Wei Xiang, Wolfgang Wurst, Ravi Jagasia, Alejandro F. Schinder, Guo-li Ming, Nicolas Toni, Sebastian Jessberger, Hongjun Song, D. Chichung Lie
Journal: Neuron (2017)
Hedgehog Signaling Is Dispensable for Adult Murine Hematopoiesis and Leukemogenesis.
Authors: Inga Hofmann Zhang, Elizabeth H. Stover, Dana E. Cullen, Junhao Mao, Kelly J. Morgan, Benjamin H. Lee, Michael G. Kharas, Peter G. Miller, Rachel Okabe, Scott A. Armstrong, Nico Ghilardi, Stephen Gould, Fred J. deSauvage, Andrew P. McMahon, D. Gary Gilliland
Journal: Blood (2008)
A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.
Authors: Animesh D. Pardanani, Jason R Gotlib, Catriona Jamieson, Jorge Cortes, Moshe Talpaz, Richard Stone, Michael H Silverman, Jolene Shorr, D. Gary Gilliland, Ayalew Tefferi
Journal: Blood (2009)
Elder mistreatment training gaps among dermatology resident physicians and opportunity to improve care of a vulnerable population: A cross-sectional study
Authors: Melissa Danesh, Julia Chang, Jillian Wong Millsop, Suzana Saric, Shufeng Li, Anne Lynn S. Chang
Journal: Journal of the American Academy of Dermatology (2017)

To the Editor: Currently, there is no formal postgraduate geriatric dermatology curriculum on elder mistreatment even though many manifestations of elder mistreatment are cutaneous.1,2 The objectives of this study were to assess whether there were significant differences in elder mistreatment training for dermatology and nondermatology adult primary care resident physicians, and whether elder mistreatment training impacts attitudes and practices toward elder mistreatment care.
Analysis and Identification of Serological Tumor Antigens in Patients Treated with the GM-CSF-Gene Transduced-Autologous Tumor Vaccines (GVAX®) for Renal Cell Carcinoma.
Authors: Yukoh Nakazaki, Takao Hashiguchi, Fuyumi Takano, Ryo Kurita, Shirley Clift, Dale G. Ando, Shigetaka Asano, Kenzaburo Tani
Journal: Blood (2004)
Response to Comment on Pathak et al. Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005–2011. Diabetes Care 2016;39:363–370
Authors: Ram D. Pathak, Emily B. Schroeder, Elizabeth R. Seaquist, Chan Zeng, Jennifer Elston Lafata, Abraham Thomas, Jean M. Lawrence, Andrew J. Karter, John F. Steiner, Jodi Segal, Patrick J. O’Connor
Journal: Diabetes Care (2017)

In a comment (1) on our article in Diabetes Care (2), Dr. Philip Home posits that the association of severe hypoglycemic events with other medical conditions and the use of diagnoses from hospitalized patients could explain the high event rate noted in our study compared with other reports based in the …
Influence of Valproic Acid on Cytokine Expression of Spleen Cells and Acute Graft-Versus-Host-Disease in a Murine Model.
Authors: Pil-Sang Jang, Dae-Hyung Lee, Young-Shil Park, Nak-Gyun Chung, Bin Cho, Dae-Chul Jeong, Hack-Ki Kim
Journal: Blood (2005)
Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis
Authors: Ruvandhi R. Nathavitharana, Patrick G.T Cudahy, Samuel G. Schumacher, Karen R. Steingart, Madhukar Pai, Claudia M. Denkinger
Journal: European Respiratory Journal (2017)

Only 25% of multidrug-resistant tuberculosis (MDR-TB) cases are currently diagnosed. Line probe assays (LPAs) enable rapid drug-susceptibility testing for rifampicin (RIF) and isoniazid (INH) resistance and Mycobacterium tuberculosis detection. Genotype MTBDRplusV1 was WHO-endorsed in 2008 but newer LPAs have since been developed. This systematic review evaluated three LPAs: Hain Genotype MTBDRplusV1, MTBDRplusV2 and Nipro NTM+MDRTB. Study quality was assessed with QUADAS-2. Bivariate random-effects meta-analyses were performed for direct and indirect testing. Results for RIF and INH resistance were compared to phenotypic and composite (incorporating sequencing) reference standards. M. tuberculosis detection results were compared to culture. 74 unique studies were included. For RIF resistance (21 225 samples), pooled sensitivity and specificity (with 95% confidence intervals) were 96.7% (95.6–97.5%) and 98.8% (98.2–99.2%). For INH resistance (20 954 samples), pooled sensitivity and specificity were 90.2% (88.2–91.9%) and 99.2% (98.7–99.5%). Results were similar for direct and indirect testing and across LPAs. Using a composite reference standard, specificity increased marginally. For M. tuberculosis detection (3451 samples), pooled sensitivity was 94% (89.4–99.4%) for smear-positive specimens and 44% (20.2–71.7%) for smear-negative specimens. In patients with pulmonary TB, LPAs have high sensitivity and specificity for RIF resistance and high specificity and good sensitivity for INH resistance. This meta-analysis provides evidence for policy and practice.
Septicemia in Chemotherapy Induced Neutropenic Acute Myeloid Leukemia (AML) Inpatients and Outpatients: A 5 Year Retrospective Experience.
Authors: Timotheus Y. Halim, Julye C. Lavoie, Micheal J. Barnett, Donna L. Forest, Donna E. Hogge, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Kevin W. Song, Heather J. Sutherland, Cynthia L. Toze, Clay A. Smith
Journal: Blood (2004)
Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients
Authors: Philipp Erben, Benjamin Hanfstein, Umang Munjal, Hannah Daikeler, Mridul Agrawal, Juliana Popa, Daniel Nowak, Armin Leitner, Dieter K Hossfeld, Hans J Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Dominik Heim, Gabriela M Baerlocher, Jörg Hasford, Hermann Heimpel, Susanne Saussele, Wolf-Karsten Hofmann, Rüdiger Hehlmann, Andreas Hochhaus, Martin C Mueller
Journal: Blood (2010)
Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma.
Authors: Yuksel Urun, Huseyin Abali, Berna Oksuzoglu, Burcin Budakoglu, Nuriye Yildirim, Tunc Guler, Gulsum Ozet, Nurullah Zengin
Journal: Blood (2007)
Gene Microdeletions in Adult and Pediatric Acute Lymphoblastic Leukemia,
Authors: Inés Gómez-Seguí, Esperanza Such, Jose Cervera, Pascual Fernandez, Lurdes Zamora, Mara Andres, Irene Luna, Mariam Ibañez, Maria López-Pavia, Beatriz Costan, Eva Barragan, Oscar Fuster, Jose Francisco Fernandez, David Martinez-Cuadrón, Leonor Senent, Silvestre Oltra, Pascual Bolufer, Amparo Verdeguer, Concha Rivas, Josep-Maria Ribera, Miguel A. Sanz
Journal: Blood (2011)
Intravenous (i.v.) or Oral (os) Busulphan (BUS) in Children Prior to Autologous (Auto) or Allogeneic (Allo) Stem Cell Transplantation (SCT): Pharmacokinetics (PK), Toxicity and Compliance.
Authors: Arcangelo Prete, Antonella Bartoli, Claudia Castellini, Roberto Rondelli, Riccardo Masetti, Andrea Pession, Mario Regazzi-Bonora
Journal: Blood (2005)
Retrospective Study of Standard R-CHOP Therapy in Localized DLBCL
Authors: Naoto Tomita, Hirotaka Takasaki, Kazuho Miyashita, Shin Fujisawa, Eriko Ogusa, Shro Matsuura, Kumiko Kishimoto, Ayumi Numata, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Katsumichi Fujimaki, Jun Taguchi, Rika Sakai, Yoshiaki Ishigatsubo
Journal: Blood (2012)
Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.
Authors: Gloria N. Mattiuzzi, Jorge E. Cortes, Stefan Faderl, Maria E. Cabanillas, Francis J. Giles, Susan O’Brien, Guillermo Garcia-Manero, Hagop H. Kantarjian
Journal: Blood (2006)
Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML).
Authors: Alvaro Urbano-Ispizua, Salut Brunet, Mariano Monzo, Granada Perea, Alfons Navarro, Jordi Esteve, Juan Berlanga, Josep-Maria Ribera, Javier Bueno, Andreu Llorente, Juan Besalduch, Ramon Guardia, Mar Tormo, Carmen Pedro, Juan-Maria Sanchez, Pio Torres, Maria-Paz Queipo de Llano, Llorens Font, Jose-Maria Moraleda, Josep-Maria Marti, Pilar Vivancos, Maria-Jesus Peñarubia, Josep Nomdedeu, Emili Montserrat, Jorge Sierra
Journal: Blood (2004)
Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines
Authors: Charlotte Pawlyn, Tim Chambers, Veronica Macleod, Daniel Sappington, Amy Buros, Caleb K. Stein, Martin F Kaiser, Rosemary Burke, Swen Hoelder, Gunnar Boysen, Ricky D Edmondson, Gareth J Morgan, Faith E Davies
Journal: Blood (2015)
Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients
Authors: Edouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, Stéphane Leprêtre, Jehan Dupuis, Pierre Feugier, Alain Devidas, Clara Mariette, Véronique Leblond, Catherine Thieblemont, Patricia Validire-Charpy, Laurent Sutton, Emmanuel Gyan, Jean-Claude Eisenmann, Xavier Troussard
Journal: Blood (2012)
Circulating Tie2-Expressing Cells Are Increased in Multiple Myeloma Patients, Correlate with Serum Pleiotrophin Levels and May Develop from This Myeloma Angiogenic and Growth Factor.
Authors: Haiming Chen, Richard A. Campbell, Melinda S. Gordon, Steven J. Manyak, Cathy Wang, Mingjie Li, Hee Jin Lee, Jennifer Wei, Howard S. Yeh, Benjamin Bonavida, James R. Berenson
Journal: Blood (2005)
Repeated Courses of Bone Marrow-Derived Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor (G-CSF) in Amyotrophic Lateral Sclerosis: Interim Analysis of a Prospective Multicenter Trial.
Authors: Corrado Tarella, Mario Melazzini, Mario Petrini, Giuseppe Leone, Rosanna Scime’, Davide Soligo, Francesca Gualandi, Cristina Moglia, Gianluigi Mancardi, Vincenzo Silani, Vincenzo La Bella, Pietro A. Tonali, Gabriele Siciliano, Gabriele Mora, Adriano Chio
Journal: Blood (2007)
Characterization of Intercellular Junctional Complexes between Human Hematopoietic and Mesenchymal Stem Cells.
Authors: Patrick Wuchter, Rainer Saffrich, Beate Straub, Judit Boda-Heggemann, Katrin Miesala, Anke Diehlmann, Wolfgang Wagner, Anja Seckinger, Ulf Krause, Werner W. Franke, Anthony D. Ho
Journal: Blood (2006)
F8 and HLA-II Haplotypes in the Hispanic Population: Implications for Inhibitor Risk Development in Hispanic Hemophilia A Patients
Authors: Benjamin Kim, Zuben E. Sauna, Melanie A. Carless, Joanne E. Curran, Kevin R. Viel, Shelley S. Cole, Rajalingam Raja, John Blangero, Tom E. Howard
Journal: Blood (2012)
Restricted Immunglobulin Gene Usage of Spleen-Derived Specific Anti-ADAMTS13 B-Cells In Relapsing TTP Treated with or without Rituximab.
Authors: Monica M. Schaller Tschan, Karin Sprecher, Irmela Sulzer, Monique Vogel, Beda Stadler, Karim Kentouche, Bernhard Lämmle, Johanna A. Kremer Hovinga Strebel
Journal: Blood (2010)
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma
Authors: Meng Zhou, Hengqiang Zhao, Wanying Xu, Siqi Bao, Liang Cheng, Jie Sun
Journal: Molecular Cancer (2017)

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and complex disease characterized by wide clinical, phenotypic and molecular heterogeneities. The expression pattern and clinical implication of long non-coding RNAs (lncRNAs) between germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes in DLBCL remain unclear. This study aims to determine whether lncRNA can serve as predictive biomarkers for subtype classification and prognosis in DLBCL.Genome-wide comparative analysis of lncRNA expression profiles were performed in a large number of DLBCL patients from Gene Expression Omnibus (GEO), including GSE31312 cohort (N = 426), GSE10846 (N = 350) cohort and GSE4475 cohort (N = 129). Novel lncRNA biomarkers associated with clinically molecular subtype and prognosis were identified in the discovery cohort using differential expression analyses and weighted voting algorithm. The predictive value of the lncRNA signature was then assessed in two independent cohorts. The functional implication of lncRNA signature was also analyzed by integrative analysis of lncRNA and mRNA.Seventeen of the 156 differentially expressed lncRNAs between GCB and ABC subtypes were identified as candidate biomarkers and integrated into form a lncRNA-based signature (termed SubSigLnc-17) which was able to discriminate between GCB and ABC subtypes with AUC of 0.974, specificity of 89.6% and sensitivity of 92.5%. Furthermore, subgroups of patients characterized by the SubSigLnc-17 demonstrated significantly different clinical outcome. The reproducible predictive power of SubSigLnc-17 in subtype classification and prognosis was successfully validated in the internal validation cohort and another two independent patient cohorts. Integrative analysis of lncRNA-mRNA suggested that these candidate lncRNA biomarkers were mainly related to immune-associated processes, such as T cell activation, leukocyte activation, lymphocyte activation and Chemokine signaling pathway.Our study uncovered differentiated lncRNA expression pattern between GCB and ABC DLBCL and identified a 17-lncRNA signature for subtype classification and prognosis prediction. With further prospective validation, our study will improve the understanding of underlying molecular heterogeneities in DLBCL and provide candidate lncRNA biomarkers in DLBCL classification and prognosis.
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.
Authors: Stefano Sacchi, Samantha Pozzi, Raffaella Marcheselli, Stefano Luminari, Massimo Federico, Alessandra Tucci, Francesco Merli, Loretta Orsucci, Giulia Cervetti, Ubaldo Occhini, Marina Liberati, Vincenzo Callea, Maura Brugiatelli, Luca Baldini
Journal: Blood (2006)
Epstein Barr Virus Micrornas Repress BCL6 Expression in Diffuse Large B Cell Lymphoma.
Authors: Daniel Martín-Pérez, Pierfrancesco Vargiu, Santiago Montes-Moreno, David G Pisano, Maria Socorro Rodriguez-Pinilla, Rufo Rodríguez, Manuela Mollejo, Josep Castellvi, Margarita Sánchez-Beato, Miguel A. Piris
Journal: Blood (2009)